First Trade Date for ICOS Corp.
|Company Name||First Trade Date (yyyy-mm-dd)|
|History and Business of Company|
(this information may include date of incorporation)
ICOS Corp. (ICOS) specializes in protein-based and small molecule therapeutics. The company combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and genomics to develop innovative products with commercial potential.|
Since its inception, ICOS has focused its research and development efforts on both protein-based and small molecule therapeutics. The company has identified novel product candidates and obtained patents for these candidates. ICOS believes that proteins and small molecules will be primary areas for pharmaceutical development for the foreseeable future, particularly as genomic research identifies novel disease targets. The company plans to continue its discovery and development efforts in these areas, emphasizing diseases and medical conditions for which current therapies are substandard or unavailable and for which the market opportunities are large.
As of Dec. 31, 2000, ICOS owned or exclusively licensed 131 U.S. patents and had 118 patent applications pending filed on its own behalf or on behalf of its joint ventures or exclusive licensors. When appropriate, ICOS also seeks foreign patent protection and as of Dec. 31, 2000, the company owned or exclusively licensed 82 foreign patents.
ICOS and its partners have the following product candidates in clinical development: Cialis, which is being developed in collaboration with Eli Lilly and is in Phase 3 clinical trials for the treatment of erectile dysfunction and in Phase 2 clinical trials for the treatment of female sexual dysfunction; Pafase, which is being developed in collaboration with Suntory for the treatment of severe sepsis and is anticipated to enter Phase 3 clinical trials in the first half of 2001; Sitaxsentan, which is being developed in collaboration with Texas Biotechnology for the treatment of pulmonary arterial hypertension and is anticipated to enter Phase 2b/3 clinical trials in the first half of 2001; TBC3711, which is being developed in collaboration with Texas Biotechnology for the treatment of congestive heart failure and essential hypertension and is in Phase 1 clinical trials; and IC14, which is in Phase 1 clinical trials for the treatment of sepsis.
INCORPORATED in Delaware Sept. 21, 1989. OFFICE- 22021 20th Avenue S.E., Bothell, WA 98021 (Tel.: 425-485-1900). Fax - 425-485-1911. WEBSITE-http://www.icos.com.
IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, The Magi Associates, Inc. and Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.
Back to first trade date main page
Back to financial astrology page
Back to home page
© 1999-2004 by Magi Associates, Inc. and Magi Astrologers Worldwide Corporation. All Rights Reserved.
Magi Astrology is a trademark and service mark of THE MAGI ASSOCIATES, INC.